Affiliation:
1. Nephrology Service, Alicante General University Hospital, 03010 Alicante, Spain
2. Pharmacy Service, Alicante General University Hospital, 03010 Alicante, Spain
3. Immunology Service, Alicante General University Hospital, 03010 Alicante, Spain
Abstract
There is uncertainty about the best approach to replacement treatment for kidney transplant recipients with chronic terminal graft dysfunction, since a retransplant could be performed before the resumption of dialysis, thus avoiding this treatment and the dilemma of whether or not to suspend immunosuppressive therapy. However, there is limited experience in pre-emptive repeat transplantations, and none from deceased donors. This study aims to assess the results of a pre-emptive retransplantation program with brain-dead deceased donors. We designed a retrospective matched cohort study, including 36 recipients in the pre-dialysis group and 36 controls who were already on dialysis, matched for donor age and transplant date, which could not differ by more than 7 days between pairs. The variables used to standardize the cohorts were donor and recipient age and sex, blood group, duration of the first graft, time on the waitlist to receive the second graft, cold ischemia time, induction and maintenance of immunosuppression, and HLA antibodies (-) prior to retransplantation. The efficacy variables were early graft loss, acute rejection, delay in graft function, renal function at the end of follow-up, survival time, and recipient and graft survival at 24 and 48 months’ follow-up. The pre-dialysis group presented a significantly shorter waitlist time, lower immunization status, and a significantly longer duration of the first graft than the control group. The percentage of recipients who presented early graft loss, delayed renal function, or acute rejection was similar between groups. No significant differences were observed in kidney function or in the survival of the recipient or graft. Retransplantation yields good outcomes in patients with terminal chronic dysfunction, helping to avoid recurrence to dialysis, shortening the time spent on the waitlist, reducing the risk of producing antibodies, and resolving the dilemma of whether or not to stop immunosuppression.
Reference26 articles.
1. Survival of cadaveric kidney transplants compared with those reciving dialysis treatment in Australia and New Zealand 1991–2001;McDonald;Nephrol. Dial. Transplant,2002
2. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant;Wolfe;N. Engl. J. Med.,1999
3. Contemporary management of renal failure: Outcome of the failed allograft recipient;Cattran;Kidney Int.,1993
4. There are 33,784 functioning kidney grafts in Spain. Who monitors them and how?;Franco;Transplant Proc.,2021
5. USRDS (2008). USRDS 2008 anual data report: Atlas of end stage renal disease in the United States national Institute of diabetes and digestive and kidney diseases: Bethedsa. Natl. Inst. Odf Health, 147.